● 截至本公告披露日，控股股东胡健先生、胡锦生先生及其一致行动人上海牧鑫私募基金管理有限公司 －牧鑫春辰1号私募证券投资基金合计持有公司股份97,926,256股，占公司总股本比例22.34%，合计持 有公司股份累计质押数量（本次解除质押后）37,900,000股，占其持股比例38.70%。 一、本次股份解除质押基本情况 ■ 证券代码：603520 证券简称：司太立 公告编号：2025-043 浙江司太立制药股份有限公司关于控股股东股份质押解除的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次解除质押人：浙江司太立制药股份有限公司（以下简称"公司"）控股股东胡锦生先生。本次解除 质押股份数量：8,820,000股（占公司总股本的2.01%,占其本人持有公司股份数的19.57%）。 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： ■ 特此公告。 浙江司太立制药股份有限公司董事会 2025年9月24日 截至本公告披露日，胡锦生先生不存在将本次解除质押股份用于后续质押的计划。 二、股东累计 ...

证券代码：603520 证券简称：司太立 公告编号：2025-043 浙江司太立制药股份有限公司 关于控股股东股份质押解除的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 一、本次股份解除质押基本情况 | | --- | 本次解除质押人：浙江司太立制药股份有限公司（以下简称"公司"） 控股股东胡锦生先生。本次解除质押股份数量：8,820,000股（占公司 总股本的2.01%,占其本人持有公司股份数的19.57%）。 截至本公告披露日，控股股东胡健先生、胡锦生先生及其一致行动人 上海牧鑫私募基金管理有限公司－牧鑫春辰1号私募证券投资基金合 计持有公司股份97,926,256股，占公司总股本比例22.34%，合计持有 公司股份累计质押数量（本次解除质押后）37,900,000股，占其持股 比例38.70%。 | | | 截至本公告披露日，胡锦生先生不存在将本次解除质押股份用于后续质押的 计划。 二、股东累计质押股份情况 截至公告披露日，上述股东及其一致行动人累计质押股份情况如下： | 股东名称 | 持股数 ...

（记者 曾健辉） 每经AI快讯，司太立9月23日晚间发布公告称，本次解除质押人为浙江司太立制药股份有限公司控股股 东胡锦生先生。本次解除质押股份数量为8,820,000股（占公司总股本的2.01%,占其本人持有公司股份数 的19.57%）。截至本公告披露日，控股股东胡健先生、胡锦生先生及其一致行动人上海牧鑫私募基金 管理有限公司－牧鑫春辰1号私募证券投资基金合计持有公司股份约9793万股，占公司总股本比例为 22.34%，合计持有公司股份累计质押数量3790万股，占其持股比例为38.7%。 每经头条（nbdtoutiao）——报价太低遭严防，投标企业还得"解释清楚"，一场国家组织的大型采购， 为何引发全行业关注 ...

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The pricing power of innovative drugs is improving, reflecting the global competitiveness of Chinese pharmaceutical companies [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions due to continued domestic substitution and accelerated overseas business progress [2]. - The neurosurgery and neurointervention fields are experiencing stable growth post-collection, with new products being launched [2]. - The high-value consumables market is expected to benefit from ongoing domestic replacement and the introduction of new products [2]. Group 3: Medical Devices - The medical device sector is seeing a recovery in bidding prices, with ongoing high-speed growth in bidding data this year [2]. - Companies are entering a phase of inventory reduction, with performance expected to improve in the second half of the year [2]. - The low-value consumables sector is experiencing product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is concentrating on central state-owned enterprises, gradually clearing the competitive landscape [2]. - The demand side is expected to see continuous upgrades to new products, with industry sentiment gradually improving [2]. Group 5: API (Active Pharmaceutical Ingredients) - The API sector is benefiting from the end of a capital expenditure peak, with three growth logic points driving upward trends: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies in the API sector are expected to see explosive growth in revenue and profits [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is witnessing a recovery in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs and ongoing observation of collection progress [2]. - The retail pharmacy sector is influenced by the pace of supply-side clearing and business model upgrades, with expectations of increased store closures in the second half of 2025 [2]. Group 8: Research and Development Services - The domestic innovative drug business development is heating up, likely driving downstream demand recovery [2]. - The overseas market presents significant growth opportunities for domestic companies, leveraging cost-effectiveness and service differentiation [2].

Core Viewpoint - The Chinese innovative drug industry is gradually catching up with Europe and the United States in terms of technology, with some targets and technical pathways already leading globally. The number and value of new drugs authorized for overseas markets continue to increase, leading to world-class pricing and non-linear investment elasticity. The domestic market is experiencing strong growth in demand, with domestic new drug sales continuing to rise, and several innovative pharmaceutical companies have turned losses into profits, entering a stable growth phase [2]. Group 1: Innovative Drugs - The innovative drug sector is witnessing a significant increase in sales driven by strong domestic demand, with a number of innovative companies achieving profitability [2]. - The trend of domestic innovative drugs going overseas is accelerating, with increasing numbers and values of new drug authorizations [2]. - The industry is positioned for a "Davis double" effect, where both performance and valuation are expected to improve [2]. Group 2: High-Value Medical Consumables - The orthopedic sector is expected to see mild price reductions, while domestic replacements continue to grow, and overseas business progresses rapidly [2]. - The neurosurgery and neurointervention fields are stabilizing after centralized procurement, with new products expected to contribute to growth [2]. Group 3: Medical Devices - The medical device sector is experiencing a high-speed growth in bidding data, with companies entering a destocking phase, which is expected to improve performance in the second half of the year [2]. - The low-value consumables sector is seeing continuous product upgrades and accelerated expansion into overseas markets [2]. Group 4: Blood Products - The supply side of the blood products industry is increasingly concentrated among state-owned enterprises, leading to a clearer competitive landscape [2]. - The demand side is expected to upgrade towards new products, gradually improving the industry's overall health [2]. Group 5: API (Active Pharmaceutical Ingredients) - The industry is at an upward turning point due to the end of a capital expenditure peak, combined with three growth drivers: new high-end market products, integrated consolidation and overseas expansion, and cost-leading CDMO [2]. - Leading companies are expected to see explosive growth in revenue and profits in the medium term [2]. Group 6: CXO (Contract Research Organization) - The CXO sector is seeing a revival in A+H financing activity, with multiple significant business developments enhancing market confidence [2]. - The focus is on optimizing the supply-side landscape and increasing market share for leading CRO companies [2]. Group 7: Traditional Chinese Medicine and Retail Pharmacy - The traditional Chinese medicine sector is showing signs of recovery, with friendly pricing for new drugs, while the retail pharmacy sector is influenced by supply-side adjustments and business model upgrades [2]. - The performance of offline pharmacies is expected to improve in the second half of 2025, with leading chains like YaoXingTang making progress in store upgrades [2]. Group 8: Research Reports - A series of in-depth research reports on various companies and sectors within the pharmaceutical and medical device industries have been published, highlighting their growth potential and market positioning [3][4].

从基金十大重仓股角度 数据显示，兴业基金旗下1只基金重仓司太立。兴业医疗保健A（011466）二季度持有股数189.91万股， 占基金净值比例为4.83%，位居第六大重仓股。根据测算，今日浮盈赚取约138.63万元。 9月15日，司太立涨6.12%，截至发稿，报12.65元/股，成交5303.89万元，换手率0.98%，总市值55.46亿 元。 资料显示，浙江司太立制药股份有限公司位于浙江省仙居县现代工业集聚区丰溪西路9号，成立日期 1997年9月15日，上市日期2016年3月9日，公司主营业务涉及X射线非离子型碘造影剂原料药系列和喹 诺酮原料药系列的生产和销售。主营业务收入构成为：造影剂系列79.73%，其他(补充)10.19%，其他 6.16%，CMO/CDMO2.41%，喹诺酮系列1.52%。 兴业医疗保健A（011466）基金经理为陈旭。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 截至发稿，陈旭累计任职时间4年193天，现任基金资产总规模 ...

Investment Rating - The report maintains a rating of "Overweight" for the pharmaceutical and biotechnology industry [2] Core Insights - Geopolitical disturbances and fluctuations in innovative drugs have limited impact on the innovation theme, while opportunities in medical devices are becoming apparent [9] - The report highlights the ongoing optimization of centralized procurement rules for medical consumables, indicating a shift from a "lowest price" approach to a "preventing excessive competition" strategy [10] - The approval process for innovative drugs is accelerating, with a new 30-day review channel established for eligible innovative drug applications [9][10] Summary by Sections Industry Overview - The pharmaceutical sector has shown a return of 26.80% since the beginning of 2025, outperforming the Shanghai Composite Index by 11.88 percentage points [14] - The report notes a mixed performance among sub-sectors, with medical devices and medical services showing positive growth while biopharmaceuticals and chemical drugs faced declines [9][14] Market Dynamics - The report indicates that the medical device sector is experiencing a recovery, with significant movements in stocks related to CRO/CDMO and medical devices [22] - Recent geopolitical news has caused short-term volatility in the innovative drug sector, but the market has quickly stabilized [9] Key Company Performance - The report recommends several companies for investment, including WuXi AppTec, WuXi Biologics, and others, which are expected to perform well in the current market environment [6][25] - The average performance of recommended stocks has shown a 6.64% increase this month, outperforming the broader pharmaceutical industry [24] Regulatory Developments - The National Medical Products Administration has announced measures to streamline the clinical trial approval process for innovative drugs, enhancing efficiency and transparency [9][12] - New procurement rules for coronary intervention balloon medical consumables have been introduced, emphasizing the need for reasonable pricing and cost commitments from bidding companies [10][12]

Investment Rating - The report maintains an "Accumulate" rating for the industry [5] Core Insights - The pharmaceutical and biotechnology industry is expected to experience a turning point and growth resonance, with a focus on the resilience of the raw material drug sector amidst various macro and micro factors [7][10] - The industry is characterized by a significant number of listed companies, totaling 494, with a total market value of 77,409.20 billion and a circulating market value of 70,487.38 billion [2] Summary by Sections Industry Overview - The report analyzes 47 representative raw material drug companies, indicating that despite pressures on revenue, the profit margins are showing improvement, reflecting the industry's resilience [10] - The average revenue growth rate for the 47 companies in the first half of 2025 was -5.38%, while the average growth rate of non-recurring net profit was 14.43% [10][12] Financial Performance - Key companies such as Xinhecheng, Aoruite, Tianyu Co., Meinuohua, and others have achieved over 10% growth in revenue and non-recurring net profit [10] - The report highlights that the non-recurring net profit of Xinhecheng increased significantly by 70.50% year-on-year in the first half of 2025 [10] Market Trends - The report notes that the prices of major raw materials are currently at low levels, particularly for certain categories like sartans and heparins, with expectations for gradual price recovery as excess capacity is cleared [7][10] - The investment strategy for the second half of the year focuses on identifying companies that are at a turning point in their existing business while also exploring new growth opportunities [7][10] Company Recommendations - The report suggests focusing on companies such as Tianyu Co., Sitaly, Tonghe Pharmaceutical, Meinuohua, Xianju Pharmaceutical, and Puluo Pharmaceutical for potential investment opportunities [7][10]

Core Points - The company announced a cash dividend distribution of 0.05 CNY per share, totaling approximately 21.92 million CNY based on a total share capital of 438,409,881 shares [1][2] - The dividend distribution plan was approved at the annual shareholders' meeting on May 22, 2025, and subsequently ratified by the board on August 28, 2025 [1][2] - The key dates for the dividend distribution include the record date on September 11, 2025, the last trading day on September 12, 2025, and the ex-dividend date also on September 12, 2025 [1][2] Dividend Distribution Details - The cash dividend will be distributed to shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the record date [2] - Shareholders who have completed designated trading can receive their cash dividends on the distribution date, while those who have not will have their dividends held by the clearing company until designated trading is completed [2] - The company will directly distribute cash dividends to specific shareholders, such as Mr. Hu Jinsheng and Mr. Hu Jian [2] Tax Implications - Individual shareholders holding unrestricted A shares for over one year will not be subject to personal income tax on the dividend, receiving the full 0.05 CNY per share [3] - For shares held for less than one year, the tax implications vary, with a maximum effective tax rate of 20% for shares held for one month or less [3][4] - Qualified Foreign Institutional Investors (QFIIs) will have a withholding tax of 10%, resulting in a net dividend of 0.045 CNY per share [6]

Group 1 - The company, Sital, announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 0.05 yuan per share (tax included) for A-shares [2] - The record date for the dividend is set for September 11, 2025, and the ex-dividend date is September 12, 2025 [2]